Key result
Discharge beta-blockers linked to ~37% lower 1-year major cardiovascular events in patients with LVEF ≤40%.
Why the study?
The study aimed to investigate the association between beta-blocker therapy and clinical outcomes in patients with AMI, particularly those with mid-range or preserved left ventricular systolic function.
Does beta-blocker therapy at discharge reduce 1-year major adverse cardiac events in patients surviving acute myocardial infarction across different LVEF categories?
Does beta-blocker therapy at discharge reduce 1-year major adverse cardiac events in patients surviving acute myocardial infarction across different LVEF categories?
Beta-blocker therapy at discharge after acute myocardial infarction is associated with improved 1-year clinical outcomes in patients with reduced or mid-range LVEF, but provides no significant benefit in those with preserved LVEF.
Answers are grounded in this paper and cite their sources.
Beta-blockers at discharge were associated with lower 1-year MACE in reduced/mid-range LVEF post-MI; leaves open randomized confirmation, especially in preserved EF.
Aims This observational study aimed to investigate the association between beta-blocker therapy and clinical outcomes in patients with acute myocardial infarction (AMI), especially with mid-range or preserved left ventricular systolic function. Methods and results Among 13 624 patients enrolled in the Korea Acute Myocardial Infarction Registry-National Institute of Health (KAMIR-NIH), 12 200 in-hospital survivors were selected. Patients with beta-blockers showed significantly lower 1-year major adverse cardiac events (MACE), which was a composite of cardiac death, MI, revascularization, and readmission due to heart failure [9.7 vs. 14.3/100 patient-year; hazard ratio (HR) 0.84, 95% confidence interval (CI) 0.72–0.97; P = 0.022). However, this association had a significant interaction with left ventricular ejection fraction (LVEF). Beta-blocker therapy at discharge was associated with lower 1-year MACE in patients with LVEF ≤40% (HR 0.63, 95% CI 0.48–0.81; P < 0.001), and 40% <LVEF < 50% (HR 0.69, 95% CI 0.51–0.94; P = 0.020), but not in patients with LVEF ≥50% (HR 1.16, 95% CI 0.91–1.48; P = 0.234). Conclusions Beta-blocker therapy at discharge was associated with better 1-year clinical outcomes in patients with reduced or mid-range LVEF after AMI, but not in patients with preserved LVEF. These data suggested that the long-term beta-blocker therapy may be guided by LVEF.
No takes yet. Share an insight, caveat, or question.
Joo et al. (2020) studied this question. Beta-blocker therapy at discharge reduced 1-year major adverse cardiac events by 37% in patients with LVEF ≤40% and 31% with 40% < LVEF < 50%.
Synapse has enriched 10 related papers. Consider them for comparative context: